Loading...
Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography
Mercurio, Valentina Hassan, Hussein J. Naranjo, Mario Cuomo, Alessandra Mazurek, Jeremy A. Forfia, Paul R. Balasubramanian, Aparna Simpson, Catherine E. Damico, Rachel L. Kolb, Todd M.
Mercurio, Valentina
Hassan, Hussein J.
Naranjo, Mario
Cuomo, Alessandra
Mazurek, Jeremy A.
Forfia, Paul R.
Balasubramanian, Aparna
Simpson, Catherine E.
Damico, Rachel L.
Kolb, Todd M.
Citations
Altmetric:
Genre
Journal article
Date
2022-07-12
Advisor
Committee member
Department
Medicine
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.3390/jcm11144034
Abstract
Background: Given the morbidity and mortality associated with pulmonary arterial hypertension (PAH), risk stratification approaches that guide therapeutic management have been previously employed. However, most patients remain in the intermediate-risk category despite initial therapy. Herein, we sought to determine whether echocardiographic parameters could improve the risk stratification of intermediate-risk patients. Methods: Prevalent PAH patients previously enrolled in observational studies at 3 pulmonary hypertension centers were included in this study. A validated PAH risk stratification approach was used to stratify patients into low-, intermediate-, and high-risk groups. Right ventricular echocardiographic parameters were used to further stratify intermediate-risk patients into intermediate-low- and intermediate-high-risk groups based on transplant-free survival. Results: From a total of 146 patients included in our study, 38 patients died over a median follow-up of 2.5 years. Patients with intermediate-/high-risk had worse echocardiographic parameters. Tricuspid annular plane systolic excursion (TAPSE) and the degree of tricuspid regurgitation (TR) were highly associated with survival (p < 0.01, p = 0.04, respectively) and were subsequently used to further stratify intermediate-risk patients. Among intermediate-risk patients, survival was worse for patients with TAPSE < 19 mm compared to those with TAPSE ≥ 19 mm (estimated one-year survival 74% vs. 96%, p < 0.01) and for patients with moderate/severe TR compared to those with no/trace/mild TR (estimated one-year survival 70% vs. 93%, p < 0.01). Furthermore, among intermediate-risk patients, those with both TAPSE < 19 mm and moderate/severe TR had an estimated one-year survival (56%) similar to that of high-risk patients (56%), and those with both TAPSE ≥ 19 mm and no/trace/mild TR had an estimated one-year survival (97%) similar to that of low-risk patients (95%). Conclusions: Echocardiography, a routinely performed, non-invasive imaging modality, plays a pivotal role in discriminating distinct survival phenotypes among prevalent intermediate-risk PAH patients using TAPSE and degree of TR. This can potentially help guide subsequent therapy.
Description
Citation
Mercurio, V.; Hassan, H.J.; Naranjo, M.; Cuomo, A.; Mazurek, J.A.; Forfia, P.R.; Balasubramanian, A.; Simpson, C.E.; Damico, R.L.; Kolb, T.M.; et al. Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography. J. Clin. Med. 2022, 11, 4034. https://doi.org/10.3390/jcm11144034
Citation to related work
MDPI
Has part
Journal of Clinical Medicine (JCM), Vol. 11, Iss. 14
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu